ESTRO 2024 - Abstract Book

S410

Brachytherapy - Urology

ESTRO 2024

Conclusion:

HDR brachytherapy had no negative impact in genitourinary or gastrointestinal toxicity compared with EBRT in these early results of patient related outcomes measures ( PROMs ) study in patients with high-risk and very-high risk prostate cancer patients.

Keywords: Brachytherapy, Prostate, PROMs

1161

Digital Poster

HDR brachytherapy as monotherapy for prostate cancer: comparison of two fractionation schedules

Magdalena Stankiewicz 1 , Maja Hasterok 2 , Monika Szołtysik 2 , Sylwia Kellas- Ślęczka 1 , Marta Szlag 3 , Piotr Wojcieszek 1

1 Maria Sklodowska-Curie National Research Institute of Oncology, Brachytherapy Department, Gliwice, Poland. 2 Maria Sklodowska-Curie National Research Institute of Oncology, Third Radiotherapy and Chemotherapy Department, Gliwice, Poland. 3 Maria Sklodowska-Curie National Research Institute of Oncology, Radiotherapy Planning Department, Gliwice, Poland

Purpose/Objective:

High dose-rate brachytherapy (HDR-BT) as monotherapy is a treatment option for localized prostate cancer. However, the data on the optimal dose and fractionation are inconsistent. In our department, we have been using this therapy since 2008. We decided to shorten and intensify our schedule with an equivalent total dose based on